[1] Hemelaar J. Implications of HIV diversity for the HIV–1 pandemic. J Infect. 2013;66:391–400.doi:10.1016/j.jinf.2012.10.026
[2] Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al. A V106M mutation in HIV–1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1–5.doi:10.1097/01.aids.0000042957.95433.6c
[3] Martinez-Cajas JL, Wainberg MA, Oliveira M, Asahchop EL, Doualla-Bell F, Lisovsky I, et al. The role of polymorphisms at position 89 in the HIV–1 protease gene in the development of drug resistance to HIV–1 protease inhibitors. J Antimicrob Chemother. 2012;67:988–94.doi:10.1093/jac/dkr582
[4] Holguin A, Sune C, Hamy F, Soriano V, Klimkait T. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV–1 variants in the absence of drug pressure. J Clin Virol. 2006;36:264–71.doi:10.1016/j.jcv.2006.05.001
[5] Santos AF, Tebit DM, Lalonde MS, Abecasis AB, Ratcliff A, Camacho RJ, et al. Effect of natural polymorphisms in the HIV–1 CRF02_AG protease on protease inhibitor hypersusceptibility. Antimicrob Agents Chemother. 2012;56:2719–25.doi:10.1128/AAC.06079–11
[6] Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, et al. Impact of HIV–1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112.doi:10.1371/journal.pmed.0020112
[7] Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, et al. Global and regional molecular epidemiology of HIV–1, 1990–2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2019;19:143–55.doi:10.1016/S1473–3099(18)30647–9
[8] Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV–1. J Clin Virol. 2004;29:152–9.doi:10.1016/S1386–6532(03)00115-X
[9] Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother. 2006;50:694–701.doi:10.1128/AAC.50.2.694–701.2006
[10] Lau KA, Wong JJ. Current Trends of HIV Recombination Worldwide. Infect Dis Rep. 2013;5:e4.doi:10.4081/idr.2013.s1.e4
[11] Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019;14:153–60.doi:10.1097/COH.0000000000000534
[12] Ode H, Matsuyama S, Hata M, Hoshino T, Kakizawa J, Sugiura W. Mechanism of drug resistance due to N88S in CRF01_AE HIV–1 protease, analyzed by molecular dynamics simulations. J Med Chem. 2007;50:1768–77.doi:10.1021/jm061158i
[13] Delviks-Frankenberry KA, Nikolenko GN, Maldarelli F, Hase S, Takebe Y, Pathak VK. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3’-azido–3’-deoxythymidine. J Virol. 2009;83:8502–13.doi:10.1128/JVI.00859–09
[14] Tanuma J, Hachiya A, Ishigaki K, Gatanaga H, Lien TT, Hien ND, et al. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV–1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors. Microbes Infect. 2010;12:1170–7.doi:10.1016/j.micinf.2010.08.003
[15] Monno L, Scudeller L, Brindicci G, Saracino A, Punzi G, Chirianni A, et al. Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naive and treated subjects. Antiviral Res. 2009;83:118–26.doi:10.1016/j.antiviral.2009.04.001
[16] Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, et al. Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine. 2017;18:225–35.doi:10.1016/j.ebiom.2017.03.024
[17] Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother. 1997;41:757–62
[18] Roge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther. 2003;8:173–82
[19] Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006;50:4182–5.doi:10.1128/AAC.00714–06
[20] McColl DJ, Chappey C, Parkin NT, Miller MD. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV–1 RT resistance mutations in a commercial database. Antivir Ther. 2008;13:189–97
[21] Ross LLG, P.; Liao, Q.; Wine, B.; Lim, M.; Shaefer, M.; Rodriguez, A.; Gallant, J.; Lanier, R. Selection for S68G/N/D Mutations of HIV–1 Reverse Transcriptase (RT) in Antiretroviral-Naïve Subjects Treated with Tenofovir (TDF)/Abacavir (ABC)/Lamivudine (3TC) Therapy. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2005:272
[22] Wirden M, Malet I, Derache A, Marcelin AG, Roquebert B, Simon A, et al. Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution. AIDS. 2005;19:630–2
[23] Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV–1 drug resistance mutations by automated DNA sequencing. Nature. 1993;365:671–3.doi:10.1038/365671a0
[24] Gibson RM, Schmotzer CL, Quinones-Mateu ME. Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use? Curr Infect Dis Rep. 2014;16:401.doi:10.1007/s11908–014–0401–5
[25] Epaulard O, Signori-Schmuck A, Larrat S, Kulkarni O, Blum MG, Fusillier K, et al. Ultradeep sequencing of B and non-B HIV–1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients. J Clin Virol. 2017;95:13–9.doi:10.1016/j.jcv.2017.07.013
[26] Garforth SJ, Lwatula C, Prasad VR. The lysine 65 residue in HIV–1 reverse transcriptase function and in nucleoside analog drug resistance. Viruses. 2014;6:4080–94.doi:10.3390/v6104080
[27] Gu Z, Arts EJ, Parniak MA, Wainberg MA. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2’,3’-dideoxycytidine 5’-triphosphate and other drugs. Proc Natl Acad Sci U S A. 1995;92:2760–4.doi:10.1073/pnas.92.7.2760
[28] Shah FS, Curr KA, Hamburgh ME, Parniak M, Mitsuya H, Arnez JG, et al. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem. 2000;275:27037–44.doi:10.1074/jbc.M002881200
[29] Garforth SJ, Domaoal RA, Lwatula C, Landau MJ, Meyer AJ, Anderson KS, et al. K65R and K65A substitutions in HIV–1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies. J Mol Biol. 2010;401:33–44.doi:10.1016/j.jmb.2010.06.001
[30] Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004;6:22–33
[31] Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, et al. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV–1 infected patients. Retrovirology. 2012;9:81.doi:10.1186/1742–4690–9–81
[32] Theys K, Abecasis AB, Vandamme AM. HIV–1 drug resistance: where do polymorphisms fit in? Future Microbiol. 2013;8:303–6.doi:10.2217/fmb.13.10
[33] Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV–1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A. 2007;104:17441–6.doi:10.1073/pnas.0708559104